JP2024523443A5 - - Google Patents
Info
- Publication number
- JP2024523443A5 JP2024523443A5 JP2023578727A JP2023578727A JP2024523443A5 JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5 JP 2023578727 A JP2023578727 A JP 2023578727A JP 2023578727 A JP2023578727 A JP 2023578727A JP 2024523443 A5 JP2024523443 A5 JP 2024523443A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213026P | 2021-06-21 | 2021-06-21 | |
| US63/213,026 | 2021-06-21 | ||
| PCT/US2022/033958 WO2022271544A1 (en) | 2021-06-21 | 2022-06-17 | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024523443A JP2024523443A (ja) | 2024-06-28 |
| JPWO2022271544A5 JPWO2022271544A5 (https=) | 2025-06-18 |
| JP2024523443A5 true JP2024523443A5 (https=) | 2025-06-18 |
Family
ID=82403446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578727A Pending JP2024523443A (ja) | 2021-06-21 | 2022-06-17 | 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250332251A1 (https=) |
| EP (1) | EP4359438A1 (https=) |
| JP (1) | JP2024523443A (https=) |
| KR (1) | KR20240024929A (https=) |
| CN (1) | CN117500834A (https=) |
| WO (1) | WO2022271544A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| US20190060241A1 (en) * | 2016-04-13 | 2019-02-28 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| MX2019004775A (es) | 2016-11-03 | 2019-08-05 | Squibb Bristol Myers Co | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos. |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| US20220233709A1 (en) * | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
-
2022
- 2022-06-17 EP EP22738290.0A patent/EP4359438A1/en active Pending
- 2022-06-17 JP JP2023578727A patent/JP2024523443A/ja active Pending
- 2022-06-17 WO PCT/US2022/033958 patent/WO2022271544A1/en not_active Ceased
- 2022-06-17 KR KR1020247001907A patent/KR20240024929A/ko active Pending
- 2022-06-17 US US18/572,479 patent/US20250332251A1/en active Pending
- 2022-06-17 CN CN202280043695.4A patent/CN117500834A/zh active Pending